Erythropoietin does not modify the prothrombotic effect induced by uremic media on endothelial cells.
Recombinant human erythropoietin (rHuEPO) administration has been associated with an increased risk of hypertension and thrombosis in uremic patients. rHuEPO and endothelial cells cultured in an uremic environment. Results indicate that rHuEPO does not exert an additional activating effect to that caused by the uremic media per se.